ArticleConflict and health2026
From HIV testing to ART initiation under fire: joinpoint regression analysis of regional disparities during the full-scale war against Ukraine.
Article in Conflict and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe full-scale Russian invasion of Ukraine in February 2022 caused large-scale displacement and major disruption of health services. We assessed national and subnational trends in HIV testing, test positivity, number of newly registered HIV cases, and antiretroviral therapy (ART) initiation during 2020-2023, and examined whether trajectories differed by regional exposure to hostilities.
methodsThis ecological time-series study analyzed routine national surveillance and program data from January 2020 through December 2023. Joinpoint regression was used to identify trend breakpoints and estimate quarterly percent change (QPC), average quarterly percent change (AQPC), monthly percent change (MPC), and average monthly percent change (AMPC), with 95% confidence intervals. Subnational analyses were stratified into three categories of exposure to hostilities: active hostilities in 2023, history of active hostilities in 2022 but not in 2023, and no active hostilities or occupation during 2022-2023.
resultsNational HIV testing declined through 2021 and dropped sharply at invasion onset, followed by sustained increases after Q2 2022 (QPC + 9.14% [95% CI: 3.89; 22.47]), exceeding pre-war levels by late 2023. However, the number of positive tests decreased steadily from 5,458 in Q1 2020 to 3,590 in Q4 2023 (AQPC -3.25% [-4.86; -1.56]) and test positivity dropped from approximately 1% to 0.5% after Q2 2022 (QPC -10.48% [-22.04; -5.99]). Newly registered HIV cases were stable through 2021, declined sharply at invasion onset, briefly rebounded, and then decreased through December 2023 (MPC -1.12% [-2.39 to -0.31]). ART initiation decreased steadily from 1,495 in January 2020 to 797 in December 2023 (AMPC -1.11% [-1.40; -0.81]), without breakpoints. Post-invasion trajectories diverged regionally: regions exposed to prolonged hostilities experienced the deepest and most persistent disruptions, whereas less affected regions demonstrated gradual increases in registrations and ART initiation.
conclusionsThe full-scale war caused substantial disruption in key HIV services. Although testing increased after the initial shock, it did not translate into higher case detection, reflecting a shift from testing high-risk populations toward war-related expanded screening of blood donors, military personnel, and displaced individuals. Regional divergence in trends was consistent with population displacement and redistribution of HIV service delivery. Interpretation of wartime HIV indicators requires attention to changes in the tested population and regional service capacity. Sustaining epidemic control under prolonged war will require combining targeted case-finding with broader screening, and strengthening cross-region linkage from diagnosis to ART initiation.
Indexed as
Identifiers
42163375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.